Pathogenic Role of the Sphingosine 1-Phosphate (S1P) Pathway in Common Gynecologic Disorders (GDs): A Possible Novel Therapeutic Target
Abstract
:1. Introduction
2. Sphingosine 1-Phosphate
3. S1P Pathway and Common Gynecologic Disorders (GDs)
3.1. S1P and Endometriosis
3.2. S1P and Adenomyosis
3.3. S1P and Uterine Fibroids
3.4. S1P and Other Gynecological Diseases
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Maceyka, M.; Harikumar, K.B.; Milstien, S.; Spiegel, S. Sphingosine-1-Phosphate Signaling and Its Role in Disease. Trends Cell Biol. 2012, 22, 50–60. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bernacchioni, C.; Capezzuoli, T.; Vannuzzi, V.; Malentacchi, F.; Castiglione, F.; Cencetti, F.; Ceccaroni, M.; Donati, C.; Bruni, P.; Petraglia, F. Sphingosine 1-Phosphate Receptors Are Dysregulated in Endometriosis: Possible Implication in Transforming Growth Factor β-Induced Fibrosis. Fertil. Steril. 2021, 115, 501–511. [Google Scholar] [CrossRef] [PubMed]
- Bernacchioni, C.; Ciarmela, P.; Vannuzzi, V.; Greco, S.; Vannuccini, S.; Malentacchi, F.; Pellegrino, P.; Capezzuoli, T.; Sorbi, F.; Cencetti, F.; et al. Sphingosine 1-Phosphate Signaling in Uterine Fibroids: Implication in Activin A pro-Fibrotic Effect. Fertil. Steril. 2021, 115, 1576–1585. [Google Scholar] [CrossRef] [PubMed]
- Islam, M.S.; Akhtar, M.M.; Segars, J.H. S1P and Activin A Induce Fibrotic Phenotype in Uterine Fibroids: A Promising Target for Antifibrotic Therapy. Fertil. Steril. 2021, 115, 1451–1452. [Google Scholar] [CrossRef] [PubMed]
- Hernández-Coronado, C.G.; Guzmán, A.; Castillo-Juárez, H.; Zamora-Gutiérrez, D.; Rosales-Torres, A.M. Sphingosine-1-Phosphate (S1P) in Ovarian Physiology and Disease. Ann. Endocrinol. (Paris) 2019, 80, 263–272. [Google Scholar] [CrossRef] [PubMed]
- Donati, C.; Cencetti, F.; Bruni, P. Sphingosine 1-Phosphate Axis: A New Leader Actor in Skeletal Muscle Biology. Front. Physiol. 2013, 4, 338. [Google Scholar] [CrossRef] [Green Version]
- Cartier, A.; Hla, T. Sphingosine 1-Phosphate: Lipid Signaling in Pathology and Therapy. Science 2019, 366, eaar5551. [Google Scholar] [CrossRef]
- Liu, H.; Chakravarty, D.; Maceyka, M.; Milstien, S.; Spiegel, S. Sphingosine Kinases: A Novel Family of Lipid Kinases. Prog. Nucleic Acid Res. Mol. Biol. 2002, 71, 493–511. [Google Scholar] [CrossRef]
- Maceyka, M.; Sankala, H.; Hait, N.; Le Stunff, H.; Liu, H.; Toman, R.; Collier, C.; Zhang, M.; Satin, L.; Merrill, A. SphK1 and SphK2, Sphingosine Kinase Isoenzymes with Opposing Functions in Sphingolipid Metabolism. J. Biol. Chem. 2005, 280, 37118–37129. [Google Scholar] [CrossRef] [Green Version]
- Spiegel, S.; Milstien, S. Sphingosine-1-Phosphate: An Enigmatic Signalling Lipid. Nat. Rev. Mol. Cell Biol. 2003, 4, 397–407. [Google Scholar] [CrossRef]
- Spiegel, S.; Milstien, S. The Outs and the Ins of Sphingosine-1-Phosphate in Immunity. Nat. Rev. Immunol. 2011, 11, 403–415. [Google Scholar] [CrossRef] [PubMed]
- Morris, A.; Selim, S.; Salous, A.; Smyth, S. Blood Relatives: Dynamic Regulation of Bioactive Lysophosphatidic Acid and Sphingosine-1-Phosphate Metabolism in the Circulation. Trends Cardiovasc. Med. 2009, 19, 135–140. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kihara, A.; Mitsutake, S.; Mizutani, Y.; Igarashi, Y. Metabolism and Biological Functions of Two Phosphorylated Sphingolipids, Sphingosine 1-Phosphate and Ceramide 1-Phosphate. Prog. Lipid Res. 2007, 46, 126–144. [Google Scholar] [CrossRef] [PubMed]
- Maceyka, M.; Spiegel, S. Sphingolipid Metabolites in Inflammatory Disease. Nature 2014, 510, 58–67. [Google Scholar] [CrossRef] [Green Version]
- Gupta, P.; Taiyab, A.; Hussain, A.; Alajmi, M.; Islam, A.; Hassan, M. Targeting the Sphingosine Kinase/Sphingosine-1-Phosphate Signaling Axis in Drug Discovery for Cancer Therapy. Cancers 2021, 13, 1898. [Google Scholar] [CrossRef]
- Tsoutsou, P.G.; Koukourakis, M.I. Radiation Pneumonitis and Fibrosis: Mechanisms Underlying Its Pathogenesis and Implications for Future Research. Int. J. Radiat. Oncol. Biol. Phys. 2006, 66, 1281–1293. [Google Scholar] [CrossRef]
- Wynn, T.A. Integrating Mechanisms of Pulmonary Fibrosis. J. Exp. Med. 2011, 208, 1339–1350. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Donati, C.; Cencetti, F.; Bruni, P. New Insights into the Role of Sphingosine 1-Phosphate and Lysophosphatidic Acid in the Regulation of Skeletal Muscle Cell Biology. Biochim. Biophys. Acta 2013, 1831, 176–184. [Google Scholar] [CrossRef]
- Li, M.; Abdollahi, A.; Gröne, H.-J.; Lipson, K.E.; Belka, C.; Huber, P.E. Late Treatment with Imatinib Mesylate Ameliorates Radiation-Induced Lung Fibrosis in a Mouse Model. Radiat. Oncol. 2009, 4, 66. [Google Scholar] [CrossRef] [Green Version]
- Sahu, S.K.; Hannun, Y.A.; Yao, N. Emergence of Membrane Sphingolipids as a Potential Therapeutic Target. Biochimie 2019, 158, 257–264. [Google Scholar] [CrossRef]
- Tsai, H.-C.; Han, M.H. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation. Drugs 2016, 76, 1067–1079. [Google Scholar] [CrossRef] [PubMed]
- Kappos, L.; Bar-Or, A.; Cree, B.; Fox, R.; Giovannoni, G.; Gold, R.; Vermersch, P.; Arnold, D.; Arnould, S.; Scherz, T.; et al. Siponimod versus Placebo in Secondary Progressive Multiple Sclerosis (EXPAND): A Double-Blind, Randomised, Phase 3 Study. Lancet 2018, 391, 1263–1273. [Google Scholar] [CrossRef]
- Scott, L. Siponimod: A Review in Secondary Progressive Multiple Sclerosis. CNS Drugs 2020, 34, 1191–1200. [Google Scholar] [CrossRef] [PubMed]
- Galvani, S.; Sanson, M.; Blaho, V.; Swendeman, S.; Obinata, H.; Conger, H.; Dahlbäck, B.; Kono, M.; Proia, R.; Smith, J.D.; et al. HDL-Bound Sphingosine 1-Phosphate Acts as a Biased Agonist for the Endothelial Cell Receptor S1P1 to Limit Vascular Inflammation. Sci. Signal. 2015, 8, ra79. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Murakami, K.; Kohno, M.; Kadoya, M.; Nagahara, H.; Fujii, W.; Seno, T.; Yamamoto, A.; Oda, R.; Fujiwara, H.; Kubo, T.; et al. Knock out of S1P3 Receptor Signaling Attenuates Inflammation and Fibrosis in Bleomycin-Induced Lung Injury Mice Model. PLoS ONE 2014, 9, e106792. [Google Scholar] [CrossRef]
- Fan, X.; Liu, L.; Shi, Y.; Guo, F.; He, X.; Zhao, X.; Zhong, D.; Li, G. Recent Advances of the Function of Sphingosine 1-Phosphate (S1P) Receptor S1P3. J. Cell Physiol. 2021, 236, 1564–1578. [Google Scholar] [CrossRef]
- Schnute, M.; McReynolds, M.; Kasten, T.; Yates, M.; Jerome, G.; Rains, J.; Hall, T.; Chrencik, J.; Kraus, M.; Cronin, C. Modulation of Cellular S1P Levels with a Novel, Potent and Specific Inhibitor of Sphingosine Kinase-1. Biochem. J. 2012, 444, 79–88. [Google Scholar] [CrossRef] [Green Version]
- Kharel, Y.; Mathews, T.; Gellett, A.; Tomsig, J.; Kennedy, P.; Moyer, M.; Macdonald, T.; Lynch, K. Sphingosine Kinase Type 1 Inhibition Reveals Rapid Turnover of Circulating Sphingosine 1-Phosphate. Biochem. J. 2011, 440, 345–353. [Google Scholar] [CrossRef] [Green Version]
- Matanes, F.; Twal, W.O.; Hammad, S.M. Sphingolipids as Biomarkers of Disease. Adv. Exp. Med. Biol. 2019, 1159, 109–138. [Google Scholar] [CrossRef]
- Eskenazi, B.; Warner, M.L. Epidemiology of Endometriosis. Obstet. Gynecol. Clin. N. Am. 1997, 24, 235–258. [Google Scholar] [CrossRef]
- Nnoaham, K.E.; Hummelshoj, L.; Webster, P.; d’Hooghe, T.; de Cicco Nardone, F.; de Cicco Nardone, C.; Jenkinson, C.; Kennedy, S.H.; Zondervan, K.T. World Endometriosis Research Foundation Global Study of Women’s Health consortium Impact of Endometriosis on Quality of Life and Work Productivity: A Multicenter Study across Ten Countries. Fertil. Steril. 2011, 96, 366–373.e8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Berkley, K.J.; Rapkin, A.J.; Papka, R.E. The Pains of Endometriosis. Science 2005, 308, 1587–1589. [Google Scholar] [CrossRef] [PubMed]
- Kitawaki, J.; Kado, N.; Ishihara, H.; Koshiba, H.; Kitaoka, Y.; Honjo, H. Endometriosis: The Pathophysiology as an Estrogen-Dependent Disease. J. Steroid Biochem. Mol. Biol. 2002, 83, 149–155. [Google Scholar] [CrossRef]
- Zeitoun, K.; Takayama, K.; Sasano, H.; Suzuki, T.; Moghrabi, N.; Andersson, S.; Johns, A.; Meng, L.; Putman, M.; Carr, B.; et al. Deficient 17beta-Hydroxysteroid Dehydrogenase Type 2 Expression in Endometriosis: Failure to Metabolize 17beta-Estradiol. J. Clin. Endocrinol. Metab. 1998, 83, 4474–4480. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Noble, L.S.; Takayama, K.; Zeitoun, K.M.; Putman, J.M.; Johns, D.A.; Hinshelwood, M.M.; Agarwal, V.R.; Zhao, Y.; Carr, B.R.; Bulun, S.E. Prostaglandin E2 Stimulates Aromatase Expression in Endometriosis-Derived Stromal Cells. J. Clin. Endocrinol. Metab. 1997, 82, 600–606. [Google Scholar] [CrossRef]
- Bulun, S.E.; Cheng, Y.-H.; Yin, P.; Imir, G.; Utsunomiya, H.; Attar, E.; Innes, J.; Julie Kim, J. Progesterone Resistance in Endometriosis: Link to Failure to Metabolize Estradiol. Mol. Cell. Endocrinol. 2006, 248, 94–103. [Google Scholar] [CrossRef]
- MacLean, J.A., II; Hayashi, K. Progesterone Actions and Resistance in Gynecological Disorders. Cells 2022, 11, 647. [Google Scholar] [CrossRef]
- Attia, G.R.; Zeitoun, K.; Edwards, D.; Johns, A.; Carr, B.R.; Bulun, S.E. Progesterone Receptor Isoform A but Not B Is Expressed in Endometriosis. J. Clin. Endocrinol. Metab. 2000, 85, 2897–2902. [Google Scholar] [CrossRef] [Green Version]
- Burney, R.O.; Talbi, S.; Hamilton, A.E.; Vo, K.C.; Nyegaard, M.; Nezhat, C.R.; Lessey, B.A.; Giudice, L.C. Gene Expression Analysis of Endometrium Reveals Progesterone Resistance and Candidate Susceptibility Genes in Women with Endometriosis. Endocrinology 2007, 148, 3814–3826. [Google Scholar] [CrossRef] [Green Version]
- Nothnick, W. MicroRNAs and Progesterone Receptor Signaling in Endometriosis Pathophysiology. Cells 2022, 11, 1096. [Google Scholar] [CrossRef]
- Burney, R.O.; Giudice, L.C. Pathogenesis and Pathophysiology of Endometriosis. Fertil. Steril. 2012, 98, 511–519. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Laschke, M.W.; Menger, M.D. Basic Mechanisms of Vascularization in Endometriosis and Their Clinical Implications. Hum. Reprod. Update 2018, 24, 207–224. [Google Scholar] [CrossRef] [PubMed]
- Rocha, A.L.L.; Reis, F.M.; Taylor, R.N. Angiogenesis and Endometriosis. Obstet. Gynecol. Int. 2013, 2013, e859619. [Google Scholar] [CrossRef] [Green Version]
- Ader, I.; Malavaud, B.; Cuvillier, O. When the Sphingosine Kinase 1/Sphingosine 1-Phosphate Pathway Meets Hypoxia Signaling: New Targets for Cancer Therapy. Cancer Res. 2009, 69, 3723–3726. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Proia, R.; Hla, T. Emerging Biology of Sphingosine-1-Phosphate: Its Role in Pathogenesis and Therapy. J. Clin. Investig. 2015, 125, 1379–1387. [Google Scholar] [CrossRef] [Green Version]
- Rudzitis-Auth, J.; Christoffel, A.; Menger, M.D.; Laschke, M.W. Targeting Sphingosine Kinase-1 with the Low MW Inhibitor SKI-5C Suppresses the Development of Endometriotic Lesions in Mice. Br. J. Pharmacol. 2021, 178, 4104–4118. [Google Scholar] [CrossRef]
- Yoshino, O.; Yamada-Nomoto, K.; Kano, K.; Ono, Y.; Kobayashi, M.; Ito, M.; Yoneda, S.; Nakashima, A.; Shima, T.; Onda, T.; et al. Sphingosine 1 Phosphate (S1P) Increased IL-6 Expression and Cell Growth in Endometriotic Cells. Reprod. Sci. 2019, 26, 1460–1467. [Google Scholar] [CrossRef]
- Ono, Y.; Kawakita, T.; Yoshino, O.; Sato, E.; Kano, K.; Ohba, M.; Okuno, T.; Ito, M.; Koga, K.; Honda, M.; et al. Sphingosine 1-Phosphate (S1P) in the Peritoneal Fluid Skews M2 Macrophage and Contributes to the Development of Endometriosis. Biomedicines 2021, 9, 1519. [Google Scholar] [CrossRef]
- Bergqvist, A.; Bruse, C.; Carlberg, M.; Carlström, K. Interleukin 1beta, Interleukin-6, and Tumor Necrosis Factor-Alpha in Endometriotic Tissue and in Endometrium. Fertil. Steril. 2001, 75, 489–495. [Google Scholar] [CrossRef]
- Santulli, P.; Marcellin, L.; Noël, J.-C.; Borghese, B.; Fayt, I.; Vaiman, D.; Chapron, C.; Méhats, C. Sphingosine Pathway Deregulation in Endometriotic Tissues. Fertil. Steril. 2012, 97, 904–911. [Google Scholar] [CrossRef]
- Hla, T.; Lee, M.J.; Ancellin, N.; Paik, J.H.; Kluk, M.J. Lysophospholipids—Receptor Revelations. Science 2001, 294, 1875–1878. [Google Scholar] [CrossRef] [PubMed]
- Salous, A.; Panchatcharam, M.; Sunkara, M.; Mueller, P.; Dong, A.; Wang, Y.; Graf, G.; Smyth, S.; Morris, A. Mechanism of Rapid Elimination of Lysophosphatidic Acid and Related Lipids from the Circulation of Mice. J. Lipid Res. 2013, 54, 2775–2784. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Venkataraman, K.; Lee, Y.; Michaud, J.; Thangada, S.; Ai, Y.; Bonkovsky, H.; Parikh, N.; Habrukowich, C.; Hla, T. Vascular Endothelium as a Contributor of Plasma Sphingosine 1-Phosphate. Circ. Res. 2008, 102, 669–676. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vannuccini, S.; Petraglia, F. Recent Advances in Understanding and Managing Adenomyosis. F1000Res 2019, 8, 283. [Google Scholar] [CrossRef] [Green Version]
- Gunther, R.; Walker, C. Adenomyosis. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2022. [Google Scholar]
- Vannuccini, S.; Luisi, S.; Tosti, C.; Sorbi, F.; Petraglia, F. Role of Medical Therapy in the Management of Uterine Adenomyosis. Fertil. Steril. 2018, 109, 398–405. [Google Scholar] [CrossRef] [Green Version]
- Wong, S.; Ray, C.E. Adenomyosis—An Overview. Semin. Interv. Radiol. 2022, 39, 119–122. [Google Scholar] [CrossRef]
- Vannuzzi, V.; Bernacchioni, C.; Muccilli, A.; Castiglione, F.; Nozzoli, F.; Vannuccini, S.; Capezzuoli, T.; Ceccaroni, M.; Bruni, P.; Donati, C.; et al. Sphingosine 1-Phosphate Pathway Is Dysregulated in Adenomyosis. Reprod. Biomed. Online 2022, 45, 15–18. [Google Scholar] [CrossRef]
- Stewart, E.; Cookson, C.; Gandolfo, R.; Schulze-Rath, R. Epidemiology of Uterine Fibroids: A Systematic Review. BJOG Int. J. Obstet. Gynaecol. 2017, 124, 1501–1512. [Google Scholar] [CrossRef] [Green Version]
- Chegini, N. Proinflammatory and Profibrotic Mediators: Principal Effectors of Leiomyoma Development as a Fibrotic Disorder. Semin. Reprod. Med. 2010, 28, 180–203. [Google Scholar] [CrossRef]
- Islam, M.S.; Protic, O.; Stortoni, P.; Grechi, G.; Lamanna, P.; Petraglia, F.; Castellucci, M.; Ciarmela, P. Complex Networks of Multiple Factors in the Pathogenesis of Uterine Leiomyoma. Fertil. Steril. 2013, 100, 178–193. [Google Scholar] [CrossRef]
- Leppert, P.C.; Baginski, T.; Prupas, C.; Catherino, W.H.; Pletcher, S.; Segars, J.H. Comparative Ultrastructure of Collagen Fibrils in Uterine Leiomyomas and Normal Myometrium. Fertil. Steril. 2004, 82, 1182–1187. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Malik, M.; Norian, J.; McCarthy-Keith, D.; Britten, J.; Catherino, W.H. Why Leiomyomas Are Called Fibroids: The Central Role of Extracellular Matrix in Symptomatic Women. Semin. Reprod. Med. 2010, 28, 169–179. [Google Scholar] [CrossRef] [PubMed]
- Reis, F.M.; Bloise, E.; Ortiga-Carvalho, T.M. Hormones and Pathogenesis of Uterine Fibroids. Best Pract. Res. Clin. Obstet. Gynaecol. 2016, 34, 13–24. [Google Scholar] [CrossRef] [PubMed]
- Orciani, M.; Caffarini, M.; Biagini, A.; Lucarini, G.; Delli Carpini, G.; Berretta, A.; Di Primio, R.; Ciavattini, A. Chronic Inflammation May Enhance Leiomyoma Development by the Involvement of Progenitor Cells. Stem Cells Int. 2018, 2018, 1716246. [Google Scholar] [CrossRef]
- Lazzarini, R.; Caffarini, M.; Delli Carpini, G.; Ciavattini, A.; Di Primio, R.; Orciani, M. From 2646 to 15: Differentially Regulated MicroRNAs between Progenitors from Normal Myometrium and Leiomyoma. Am. J. Obstet. Gynecol. 2020, 222, 596.e1–596.e9. [Google Scholar] [CrossRef]
- Ciavattini, A.; Clemente, N.; Delli Carpini, G.; Di Giuseppe, J.; Giannubilo, S.R.; Tranquilli, A.L. Number and Size of Uterine Fibroids and Obstetric Outcomes. J. Matern.-Fetal Neonatal Med. 2015, 28, 484–488. [Google Scholar] [CrossRef]
- Islam, M.S.; Ciavattini, A.; Petraglia, F.; Castellucci, M.; Ciarmela, P. Extracellular Matrix in Uterine Leiomyoma Pathogenesis: A Potential Target for Future Therapeutics. Hum. Reprod. Update 2018, 24, 59–85. [Google Scholar] [CrossRef] [Green Version]
- Bao, H.; Sin, T.K.; Zhang, G. Activin A Induces Leiomyoma Cell Proliferation, Extracellular Matrix (ECM) Accumulation and Myofibroblastic Transformation of Myometrial Cells via P38 MAPK. Biochem. Biophys. Res. Commun. 2018, 504, 447–453. [Google Scholar] [CrossRef]
- Islam, M.S.; Catherino, W.H.; Protic, O.; Janjusevic, M.; Gray, P.C.; Giannubilo, S.R.; Ciavattini, A.; Lamanna, P.; Tranquilli, A.L.; Petraglia, F.; et al. Role of Activin-A and Myostatin and Their Signaling Pathway in Human Myometrial and Leiomyoma Cell Function. J. Clin. Endocrinol. Metab. 2014, 99, E775–E785. [Google Scholar] [CrossRef] [Green Version]
- Hernández-Coronado, C.G.; Guzmán, A.; Espinosa-Cervantes, R.; Romano, M.C.; Verde-Calvo, J.R.; Rosales-Torres, A.M. Sphingosine-1-Phosphate and Ceramide Are Associated with Health and Atresia of Bovine Ovarian Antral Follicles. Animal 2015, 9, 308–312. [Google Scholar] [CrossRef]
- Becker, S.; von Otte, S.; Robenek, H.; Diedrich, K.; Nofer, J.-R. Follicular Fluid High-Density Lipoprotein-Associated Sphingosine 1-Phosphate (S1P) Promotes Human Granulosa Lutein Cell Migration via S1P Receptor Type 3 and Small G-Protein RAC1. Biol. Reprod. 2011, 84, 604–612. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Guzel, Y.; Bildik, G.; Oktem, O. Sphingosine-1-Phosphate Protects Human Ovarian Follicles from Apoptosis In Vitro. Eur. J. Obstet. Gynecol. Reprod. Biol. 2018, 222, 19–24. [Google Scholar] [CrossRef] [PubMed]
- Li, S.; Chen, J.; Fang, X.; Xia, X. Sphingosine-1-Phosphate Activates the AKT Pathway to Inhibit Chemotherapy Induced Human Granulosa Cell Apoptosis. Gynecol. Endocrinol. 2017, 33, 476–479. [Google Scholar] [CrossRef] [PubMed]
- Kono, M.; Mi, Y.; Liu, Y.; Sasaki, T.; Allende, M.L.; Wu, Y.-P.; Yamashita, T.; Proia, R.L. The Sphingosine-1-Phosphate Receptors S1P1, S1P2, and S1P3 Function Coordinately during Embryonic Angiogenesis. J. Biol. Chem. 2004, 279, 29367–29373. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Olivera, A.; Spiegel, S. Sphingosine-1-Phosphate as Second Messenger in Cell Proliferation Induced by PDGF and FCS Mitogens. Nature 1993, 365, 557–560. [Google Scholar] [CrossRef]
- Cuvillier, O.; Pirianov, G.; Kleuser, B.; Vanek, P.G.; Coso, O.A.; Gutkind, S.; Spiegel, S. Suppression of Ceramide-Mediated Programmed Cell Death by Sphingosine-1-Phosphate. Nature 1996, 381, 800–803. [Google Scholar] [CrossRef] [PubMed]
- Knapp, P.; Baranowski, M.; Knapp, M.; Zabielski, P.; Błachnio-Zabielska, A.U.; Górski, J. Altered Sphingolipid Metabolism in Human Endometrial Cancer. Prostaglandins Other Lipid Mediat. 2010, 92, 62–66. [Google Scholar] [CrossRef] [PubMed]
- French, K.J.; Upson, J.J.; Keller, S.N.; Zhuang, Y.; Yun, J.K.; Smith, C.D. Antitumor Activity of Sphingosine Kinase Inhibitors. J. Pharmacol. Exp. Ther. 2006, 318, 596–603. [Google Scholar] [CrossRef] [Green Version]
- Dai, L.; Liu, Y.; Xie, L.; Wu, X.; Qiu, L.; Di, W. Sphingosine Kinase 1/Sphingosine-1-Phosphate (S1P)/S1P Receptor Axis Is Involved in Ovarian Cancer Angiogenesis. Oncotarget 2017, 8, 74947–74961. [Google Scholar] [CrossRef] [Green Version]
- Zhang, H.; Wang, Q.; Zhao, Q.; Di, W. MiR-124 Inhibits the Migration and Invasion of Ovarian Cancer Cells by Targeting SphK1. J. Ovarian Res. 2013, 6, 84. [Google Scholar] [CrossRef]
- Sutphen, R.; Xu, Y.; Wilbanks, G.D.; Fiorica, J.; Grendys, E.C.; LaPolla, J.P.; Arango, H.; Hoffman, M.S.; Martino, M.; Wakeley, K.; et al. Lysophospholipids Are Potential Biomarkers of Ovarian Cancer. Cancer Epidemiol. Biomark. Prev. 2004, 13, 1185–1191. [Google Scholar] [CrossRef]
- Dai, L.; Xia, P.; Di, W. Sphingosine 1-Phosphate: A Potential Molecular Target for Ovarian Cancer Therapy? Cancer Investig. 2014, 32, 71–80. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Di Paolo, A.; Vignini, A.; Alia, S.; Membrino, V.; Delli Carpini, G.; Giannella, L.; Ciavattini, A. Pathogenic Role of the Sphingosine 1-Phosphate (S1P) Pathway in Common Gynecologic Disorders (GDs): A Possible Novel Therapeutic Target. Int. J. Mol. Sci. 2022, 23, 13538. https://doi.org/10.3390/ijms232113538
Di Paolo A, Vignini A, Alia S, Membrino V, Delli Carpini G, Giannella L, Ciavattini A. Pathogenic Role of the Sphingosine 1-Phosphate (S1P) Pathway in Common Gynecologic Disorders (GDs): A Possible Novel Therapeutic Target. International Journal of Molecular Sciences. 2022; 23(21):13538. https://doi.org/10.3390/ijms232113538
Chicago/Turabian StyleDi Paolo, Alice, Arianna Vignini, Sonila Alia, Valentina Membrino, Giovanni Delli Carpini, Luca Giannella, and Andrea Ciavattini. 2022. "Pathogenic Role of the Sphingosine 1-Phosphate (S1P) Pathway in Common Gynecologic Disorders (GDs): A Possible Novel Therapeutic Target" International Journal of Molecular Sciences 23, no. 21: 13538. https://doi.org/10.3390/ijms232113538